CRBU
Price
$1.46
Change
-$0.05 (-3.31%)
Updated
Jul 31 closing price
Capitalization
144.8M
9 days until earnings call
Intraday BUY SELL Signals
GHRS
Price
$28.07
Change
-$0.31 (-1.09%)
Updated
Jul 31 closing price
Capitalization
1.93B
23 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRBU vs GHRS

CRBU vs GHRS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRBU vs. GHRS commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBU is a Buy and GHRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (CRBU: $1.46 vs. GHRS: $28.07)
Brand notoriety: CRBU and GHRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBU: 41% vs. GHRS: 52%
Market capitalization -- CRBU: $144.8M vs. GHRS: $1.93B
CRBU [@Biotechnology] is valued at $144.8M. GHRS’s [@Biotechnology] market capitalization is $1.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBU’s FA Score shows that 1 FA rating(s) are green whileGHRS’s FA Score has 0 green FA rating(s).

  • CRBU’s FA Score: 1 green, 4 red.
  • GHRS’s FA Score: 0 green, 5 red.
According to our system of comparison, GHRS is a better buy in the long-term than CRBU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBU’s TA Score shows that 3 TA indicator(s) are bullish while GHRS’s TA Score has 2 bullish TA indicator(s).

  • CRBU’s TA Score: 3 bullish, 7 bearish.
  • GHRS’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, both CRBU and GHRS are a bad buy in the short-term.

Price Growth

CRBU (@Biotechnology) experienced а -7.01% price change this week, while GHRS (@Biotechnology) price change was +2.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

CRBU is expected to report earnings on Aug 12, 2026.

GHRS is expected to report earnings on Aug 26, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GHRS($1.93B) has a higher market cap than CRBU($145M). GHRS YTD gains are higher at: 121.024 vs. CRBU (-8.176). GHRS has higher annual earnings (EBITDA): -56.03M vs. CRBU (-116.43M). GHRS has more cash in the bank: 267M vs. CRBU (118M). GHRS has less debt than CRBU: GHRS (432K) vs CRBU (26.9M). CRBU has higher revenues than GHRS: CRBU (11.2M) vs GHRS (0).
CRBUGHRSCRBU / GHRS
Capitalization145M1.93B8%
EBITDA-116.43M-56.03M208%
Gain YTD-8.176121.024-7%
P/E RatioN/AN/A-
Revenue11.2M0-
Total Cash118M267M44%
Total Debt26.9M432K6,227%
TECHNICAL ANALYSIS
Technical Analysis
CRBUGHRS
RSI
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 4 days ago
90%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRBU
Daily Signal:
Gain/Loss:
GHRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JNBSX10.740.01
+0.09%
JPMorgan Income Builder I
RMBNX54.100.04
+0.07%
RMB Mendon Financial Services C
FCBSX36.72-0.03
-0.08%
Franklin Mutual U.S. Mid Cap Value C
CBSAX26.70-0.18
-0.67%
Columbia Select Mid Cap Growth Fund A
MIDSX3.10-0.09
-2.82%
Midas Discovery

CRBU and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBU has been loosely correlated with EDIT. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBU jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBU
1D Price
Change %
CRBU100%
-3.31%
EDIT - CRBU
64%
Loosely correlated
-4.09%
CRSP - CRBU
55%
Loosely correlated
-0.93%
RXRX - CRBU
53%
Loosely correlated
-1.32%
SANA - CRBU
52%
Loosely correlated
-3.69%
BEAM - CRBU
50%
Loosely correlated
-3.66%
More

GHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GHRS has been loosely correlated with ATAI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GHRS jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GHRS
1D Price
Change %
GHRS100%
-1.09%
ATAI - GHRS
37%
Loosely correlated
N/A
RXRX - GHRS
37%
Loosely correlated
-1.32%
ABSI - GHRS
35%
Loosely correlated
+1.83%
CRBU - GHRS
34%
Loosely correlated
-3.31%
IVVD - GHRS
34%
Loosely correlated
-8.01%
More